Clinical trial
A Single-Arm Study of Adjuvant Immunotherapy Plus Anlotinib in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma With Non-Major Pathological Response and ypN-Positive Disease After Neoadjuvant Chemoimmunotherapy and Surgery
NCT07830355 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Arm Study of Adjuvant Immunotherapy Plus Anlotinib in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma With Non-Major Pathological Response and ypN-Positive Disease After Neoadjuvant Chemoimmunotherapy and Surgery
- Lead sponsor
- Shanghai Chest Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- December 31, 2029
- Enrollment
- 75 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.